Interferon alpha and autoimmunity;Interferon alpha et auto-immunite

Medecine Therapeutique

Volumn 6, Issue 1, 2000, Pages 66-74

  Papo, Thomas ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; HUMAN; IMMUNOMODULATION; PATHOPHYSIOLOGY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROIDITIS; TREATMENT INDICATION;

EID: 0034000243     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Proctor S.J., et al. 1989. Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant alpha 2b interferon. Blood 74 : 1894-1897.
2. Nicolas J.F., Thivolet J. 1989. Interferon alfa therapy in severe unresponsive subacute cutaneous lupus erythematosus. N Engl J Med 321 : 1550-1551.
3. Shiozawa S., Morimoto I., Tanaka Y., Shiozawa K. 1993. A preliminary study on the interferon alpha treatment for xerostomia of Sjögren syndrome. Br J Rheumatol 32 : 52-54.
4. Black C.M., et al. 1999. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma : results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 426 : 299-305.
5. O'Duffyj D., et al. 1998. Interferon-alpha treatment of Behcet's disease. J Rheumatol 25 : 1938-1944.
6. Bolay H., et al. 1998. Alpha interferon treatment in myasthenia gravis. Effects on natural killer cells. J Neuroimmunol 82 : 109-115.
7. Kimata H., Akiyama Y., Kubota M., Fushuro F. 1995. Interferon-alpha treatment for severe atopic dermatitis. Allergy 50 : 837-840.
8. Gasche C., et al. 1995. Prospective evaluation of interferon alpha in treatment of chronic active Crohn's disease. Dig Dis Sci 40 : 800-804.
9. Papo T., Piette J.C., Le Thi Huong D., Godeau P. 1993. Interféron alpha et autoimmunité. Ann Med Interne 144 : 357-366.
10. Friedman R.L., Stark G.R. 1985. Alpha-interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences. Nature 314 : 637-639.
11. Giacomini P., Fraioli R., Calabro A.M., Di Filippo F., Natali P.G. 1991. Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients. Cancer Res 51 : 652-656.
12. Guerin V., Todd I., Hammond L.J., Bottazzo G.F. 1990. Suppression of HLA class II expression on thyrocytes by interferon-alpha 1. Clin Exp Immunol 79 : 341-345.
13. Luft T., et al. 1998. Type 1 IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161 : 1947-1953.
14. Miossec P. 1997. Cytokine-induced autoimmune disorders. Drug safety 17 : 93-104.
15. Belardelli P., Gresser I. 1996. The neglected role of type I interferon in the T-cell response : implications of its clinical use. Immunol Today 17 : 369-372.
16. Hooks J.J., et al. 1979. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301 : 5-8.
17. Chakrabarti D., Hultgren B., Stewart T.A. 1996. IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol 157 : 522-528.
18. Karray S., Delfraissy J.F., Merle-Beral H., Wallon C., Debré P., Galanaud P. 1988. Positive effects of interferon-alpha on B cell-type chronic lymphocytic leukemia proliferative response. J Immunol 140 : 774-778.
19. Suzuki N., Sakane T., Engleman E.G. 1990. Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus. J Clin Invest 85 : 238-247.
20. Panem S., Check J., Henriksen D., Vilcek J. 1982. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J Immunol 129 : 1-3.
21. Karlsson-Parra A., et al. 1990. Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived interferon-alpha (IFN-alpha). Clin Exp Immunol 81 : 72-75.
22. Magnone M., et al. 1995. Interféron-alpha induced acute renal allograft rejection. Transplantation 59 : 1068-1070.
23. Gadano A.C., et al. 1995. Alpha-interféron-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen. Transplantation 59 : 1627-1629.
24. Dousset B., Conti F., Houssin D., Calmus Y. 1994. Acute vanishing bile duct syndrome after interferon therapy for reccurrent HCV infection in liver-transplant recipients. N Engl J Med 330 : 1160-1161.
25. Browett P.J., Nelson J., Tiwari S. 1994. Graft-versus-host disease following interferon therapy for relapsed chronic myeloid leukemia post-allogeneic bone marrow transplantation. Bone Marow Tranplant 14 : 641-644.
26. Conlon K.C., Urba W.J., Smith J.W., Steis R.G., Longo D.L., Clark J.W. 1990. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65 : 2237-2242.
27. Figlin R.A., De Kernian J.B., Mukamel E., Palleroni A., Itri L.M., Sarna G.P. 1988. Recombinant interferon alpha-2 in metastatic renal cell carcinoma : assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol 6 : 1604-1610.
28. Mayet W.J., et al. 1989. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10 : 24-28.
29. Saracco G., et al. 1990. Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis. J Hepatol 11 : 339-343.
30. Gregorio G., et al. 1996. Autoantibody prevalence in chronic hepatitis B virus infection : effect of interferon alpha. Hepatology 24 : 520-523.
31. Steis R.G., et al. 1991. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia. Blood 4 : 792-798.
32. Quesada J.R., Talpaz M., Rios A., Kurzrock R., Gutterman J.U. 1986. Clinical toxicity of interferons in cancer patients : a review. J Clin Oncol 4 : 234-243.
33. Ronnblom L.E., Alm G.V., Oberg K.E. 1991. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Int Med 115 : 178-183.
34. Ronnblom L.E., Alm G.V., Oberg K.E. 1990. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 227 : 207-210.
35. Becker C.B., et al. 1994. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 73 : 1621-1624.
36. Chung A., Older S.A. 1997. Interferon-alpha associated arthritis. J Rheumatol 24 : 1844-1845.
37. Arai H., Tanaka M., Ohta K., Kojo T., Nijima K., Imawari M. 1995. Symptomatic myopathy associated with interferon therapy for chronic hepatitis C. Lancet 345 : 582.
38. Segawa F., Shmizu Y., Saito E., Kinoshita M. 1995. Behcet's disease induced by interferon therapy of chronic myelogenous leukemia. J Rheumatol 22 : 1183-1184.
39. Dourakis S.P., Deutsch M., Hadziyannis S.J. 1996. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol 95 : 972-975.
40. Akard L.P., Hoffman R., Elias L., Saiers J.H. 1986. Alpha-interferon and immune hemolytic anemia. Ann Intern Med 105 : 306.
41. Mangan K.F., Zidar B., Shadduk R.K., Zeigler Z., Winkelstein A. 1985. Interferon-induced aplasia : evidence for T-cell mediated suppression of hematopoiesis and recovery after treatment with horse anti-human thymocyte globulin. Am J Hematol 19 : 401-413.
42. Stricker R.B., Barlogie B., Kiprov D.D. 1994. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol 21 : 350-352.
43. Parodi A., et al. 1993. Bullous eruption wtih circulating pemphigus-like antibodies following interferon-alpha therapy. Dermatology 186 : 155-157.
44. Kirsner R.S., Anhalt G.J., Kerdel F.A. 1995. Treatment with alpha interferon associated with the development of paraneoplastic pemphigus. Br J Dermatol 132 : 474-478.
45. Scheinbenbogen C., Hunstein W., Keilholz U. 1994. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer 30A : 1209-1211.
46. Dalakos G.N., Christodoulou D., Kistis K.G., Zervou E.K., Hatzis J., Tisanos E.V. 1998. A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 10 : 933-939.
47. Quesada J.R., Gutterman J.U. 1986 Psoriasis and alpha-interferon. Lancet ii: 1466-1468.
48. Sangster C., Kaye S.B., Calman B.C., Toy J.L. 1983. Cutaneous vasculitis associated with interferon. Eur J Cancer Clin Oncol 19 : 1647-1649.
49. Larrey D., Marcellin P., Freneaux E., Pessayre D., Benhamou J.P. 1989. Exacerbation of multiple sclerosis after the administration of recombinant human interferon alpha. JAMA 261 : 2065.
50. Batocchi A.P., Evoli A., Servidei S., Palmisani M.T., Apollo F., Tonali P. 1995. Myasthenia gravis during interferon alfa therapy. Neurology 45 : 383.
51. Kukamura S., Ishikura H., Kobayashi S. 1998. Bone marrow necrosis and the Lambert-Eaton syndrome associated with interferon alpha treatment. N Engl J Med 338 : 199-200.
52. Fentiman I.S., Balkwill F.R., Thomas B.S., Russe M.J., Todd I., Bottazzo G.F. 1988. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 24 : 1299-1303.
53. Schultz M., Muller R., Von Zur Mulhen A., Brabant G. 1989. Induction of hyperthyroidism by interferon-alpha-2b. Lancet 1 : 1452.
54. Mathieu E., Fain O., Sitbon M., Thomas M. 1995. Diabète auto-immun après traitement par interféron alpha. Presse Med 24 : 238.
55. Di Cesare E., et al. 1996. Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Dig Dis Sci 41 : 1672-1677.
56. Krug J., Fritzsch J., Aust G. 1995. Induction of insulin antibodies and insulin allergy under alpha-interferon treatment of renal cell carcinoma in a patient withinsulin-treated diabetes mellitus. Int Arch Allergy Immunol 106 : 169-172.
57. Papo T., Marcellin P., Bernnuau J., Durand F., Poynard T., Benhamou J.P. 1992. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Int Med 116 : 51-53.
58. Vento S., et al. 1989. Hazards of interferon therapy for HBV-seronegative chronic hepatitis. Lancet 2 : 926.
59. D'Amico E., et al. Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C infection. Dig Dis Sci 1995 ; 40 : 2113-2116.
60. Lederer E., Truong L. 1992. Unusual glomerular lesion in a patient receiving long-term interferon treatment. Am J Kidney Dis 20 : 516-518.
61. Abdi E.A., Gia-Kahn N., Ludwig R.N., Dickout W.J. 1987. Pulmonary sarcoidosis following interferon therapy for advanced renal cancer. Cancer 59 : 896-900.
62. Kamisako T., Adachi Y., Chihara J., Yamamoto T. 1993. Interstitial pneumonitis and interferon-alfa. Br Med J 306 : 896.
63. Veerabagu M.P., Finkelstein S.D., Rabinovitz M. 1997. Granulomatous hepatitis in a patient with chronic hepatitis C treated with interteron-alpha. Dig Dis Sci 42 : 1445-1448.
64. Kanda Y., Shigeno K., Kinoshita N., Nakao K., Yano M., Matsuo H. 1994. Sudden hearing loss associated with interferon. Lancet 343 : 1134-1335.
65. Guyer D.R., et al. 1993. Interferon-associated retinopathy. Arch Ophtalmol 11 : 350-356.
66. Roti E., et al. 1996. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 172 : 482-487.
67. Chedin P., Chanson P., Duranteau L., Guillausseau P.J., Lubetzki J. 1994. Dysthyroïdies chez les malades traités par interféron alpha. Presse Med 23 : 1659-1663.
68. Fattovitch G., Giustina C., Favarrato S., Ruol. 1996. A survey of adverse events in 11 241 patients with chronic viral hepatitis treatedwith alfa interferon. J Hepatol 24 : 38-47.
69. Fentiman I.S., Thomas B.S., Balkwill F.R., Rubens R.D., Hayward J.L. 1985. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet i : 1166.
70. Burman P., Totterman T.H., Oberg K., Karlsson F.A. 1986. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metabol 63 : 1086-1090.
71. Marcellin P., et al. 1991. Thyroid dysfunction induced by recombinant alpha interferon in patients with chronic hepatitis C : a prospective study. Hepatology 14 : 77A.
72. Lazarus J.H., et al. The prevalence and progression of autoimmune thyroid disease in the elderly. Acta Endocrinol 1984 ; 106 : 199-202.
73. Weijl N.I., et al. 1993. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 11 : 1376-1383.
74. Deutsch M., et al. 1997. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 26 : 206-210.
75. Fernandez-Sotto L., et al. 1998. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during and after discontinuing interferon therapy. Arch Intern Med 158 : 1445-1448.
76. Papo T., Oksenhendler E., Izembart M., Leger A., Clauvel J.P. 1992. Anti-thyroid hormone antibodies induced by interferon alpha. J Clin Endocrinol Metab 75 : 1484-1486.
77. Franzke A., et al. 1999. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 17 : 529-533.
78. Kanayama Y., Inariba T.K., Negoro N., Akamura M., Takeda T., Inoue T. 1989. Possible involvement of interferon alfa in the pathogenesis of fever in systemic lupus erythematosus. Ann Rheum Dis 48 : 861-863.
79. Vallin H., Blomberg S., Alm G.V., Cederblad B., Ronnblom L. 1999. Patients with systemic lupus erythematosus have a circulating inducer of interferon-alpha production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 115 : 196-202.
80. Schattner A. 1988. Interferons and autoimmunity. Am J Med Sc 295 : 532-544.
81. Ramirez F., Williams R.C., Sibbitt W.L. Jr, Searles M.R.P Jr. 1986. Immunoglobulin from systemic lupus erythematosus serum induces interferon release by normal mononuclear cells. Arthritis Rheum 29 : 326-335.
82. Sergiescu D., Cerutti I., Efthymiou E., Kahan A., Chany C. 1979. Adverse effects of interferon treatment on the life span of NZB mice. Biomedicine 31 : 48-51.
83. Gresser I., Maury C., Tovey M., Morel-Maroger L., Pontillon F. 1976. Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature 263 : 420-422.
84. Schattner A., Duggan D., Naparstek Y., Schwartz R.S. 1986. Effects of interferon-alpha on the expression of a lupus idiotype in normal humans. Clin Immunol Immunopathol 38 : 327-336.
85. Kalkner K.M., et al. 1998. Antiboides against double-stranded DNA and development of polymyositis during treatment with interferon. Q J Med 91 : 393-399.
86. Schilling P.J., Kurzrock R., Kantarjian H., Gutterman J.U., Talpaz M. 1991. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68 : 1536-1537.
87. Sacchi S., Kantarjian H., O'Brien S., Cohen P.R., Pierce S., Talpaz M. 1995. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 13 : 2401-2407.
88. Garcia-Porrua C., Gonzales-Gay M.A., Fernandez-Lamelo F., Paz-Carreira J.M., Lavilla E., Gonzalez-Lopez M.A. 1998. Simultaneous development of SLE-like syndrome and auto-immune thyroiditis following alpha-interferon treatment. Clin Exp Rheumatol 16 : 107-108.
89. Wandl U.B., et al. 1992. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 65 : 70-74.
90. Preble O.T., Rothko K., Klippel J.H., Friedman R.M , Johnston M.I. 1983. Interferon-induced 2′-5′ adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med 157 : 2140-2146.
91. Nicolas J.F., Thivolet J. 1989. Interferon alfa therapy in severe unresponsive subacute cutaneous lupus erythematosus. N Engl J Med 321 : 1550-1551.
92. Thivolet J., Nicolas J.F., Kanitakis J., Lyonnet S., Chouvet B. 1990. Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus. Br J Dermatol 122 : 405-409.
93. Becker J.C., Winclker B., Klingen S., Brocker E.B. 1994. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer73 : 1621 - 1624.
94. Durand J.M., Quiles N., Kaplanski C. 1993. Thrombosis and recombinant interferon-alpha. Am J Med 95 : 115-116.
95. Jadoul M., et al. 1995. Renal thrombotic microangiopathy in patients with chronic myelogenous leukemia treated with interferon-alpha-2b. Nephrol Dial Transplant 10 : 111-113.
96. Homberg J.C., et al. 1987. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1 : a second type of «autoimmune» hepatitis. Hepatology 7 : 1333-1339.
97. Ruiz-Moreno M., et al. 1991. Autoimmune chronic hepatitis type 2 manifested during interferon therapy in children. J Hepatol 12 : 265-266.
98. Davis G.L., et al., and the Hepatitis International Therapy Group. 1989. Treatment of chronic hepatitis C with recombinant Interferon alpha. N Engl J Med 321 : 1301-1506.
99. Mishiro S., et al. 1990. Non-A, non-B hepatitis specific antibodies directed at a host-derived epitope : implication for an auto immune process. Lancet 336 : 1400-1403.
100. Michel G., et al. 1992. Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet 339 : 267-269.
101. Kerkar N., et al. 1999. A novel assay for detecting antibodies to cytochrome P4502D6, the molecular target of liver kidney microsomal antibody type 1. J Immunol Methods 223 : 227-235.
102. Duclos Vallée J.C., et al. 1998. Interferon therapy in LKM-1 positive patients with chronic hepatitis C : follow-up by a quantitative radioligand assay for CYP2D6 antibody detection. J Hepatol 28 : 965-970.
103. Vento S., Cainelli F, Renzini C, Concia E. 1997. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet 350 : 1298-1299.
104. Cassani F., et al. 1997. Serum autoantibodies in chronic hepatitis C : comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 26 : 561-566.
105. Durelli L., Bongianni M.R., Ferrero B., Oggero A., Marzano A., Rizzeto M. 1998. Interferon treatment for multiple sclerosis : autoimmune complications may be lethal. Neurology 50 : 570-571.
106. Bellary S., Schiano T., Hartman C., Black M. 1995. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C : favorable response to prednisone and azathioprine. Ann Intern Med 123 : 32-34.
107. Garcia-Buey L., et al. 1995. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 108 : 1770-1777.
108. Kamayoglu S., et al. 1998. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis ? J Hepatol 28 : 78-83.